Johnson & Johnson submitted a BLA to the FDA for nipocalimab, a potential treatment for generalized myasthenia gravis. Data from the Vivacity-MG3 study showed sustained disease control in gMG patients.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing